Treatment of RCC cell lines with sunitinib induced senescence characteristics such as SA-β-gal activity, the SASP (IL-1, IL-6, and IL-8), and expression of Decoy Receptor 2 (DcR2) and Deleted in Esophageal Cancer 1 (Dec1). Here, DELEC1 is linked to renal cell carcinoma.